BIIB019 (Daclizumab)

BIOLOGICAL3 trials

Sponsors

Biogen

Conditions

Multiple SclerosisRelapsing-Remitting Multiple Sclerosis

Phase 2

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

CompletedNCT01051349

BiogenRelapsing-Remitting Multiple Sclerosis

Start: 2010-03-31End: 2016-08-25Updated: 2018-11-09

Phase 3

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

CompletedNCT01462318

BiogenRelapsing-Remitting Multiple Sclerosis

Start: 2011-11-30End: 2016-01-31Updated: 2017-03-14

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019

TerminatedNCT01797965

BiogenMultiple Sclerosis, Relapsing-Remitting Multiple Sclerosis

Start: 2013-02-15End: 2018-09-24Updated: 2019-12-04

Related Papers

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Therapeutic Advances in Neurological Disorders2021-01-016 citations

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Journal of Neurology2020-05-2511 citations

MRI Outcomes in Patients Treated with Daclizumab in the EXTEND Open-Label Extension Study: Interim Report at Week 48 (P5.343)

Neurology2017-04-18

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.

2016-07-2635 citations

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.

2016-07-1314 citations